Vertaling van "filings are expected this year " (Nederlands → Frans) :

Regulatory filings are expected this year in pancreatic neuroendocrine tumors (pNET) following data showing Afinitor met the primary endpoint of progression-free survival in a Phase III study of pNET.
A la suite de résultats d’une étude de phase III consacrée aux tumeurs neuroendocrines du pancréas (pTNE) montrant qu’Afinitor satisfaisait au critère principal de survie sans progression de la maladie, des demandes d’autorisation devraient être déposées cette année.

Onbrez Breezhaler has since been launched in Ireland and Denmark in March 2010 with additional launches expected this year in 20 markets, including the UK, Spain, Brazil and Mexico.
Depuis, Onbrez Breezhaler a été lancé en mars en Irlande et au Danemark et d’autres lancements sont prévus cette année dans vingt marchés, dont le Royaume-Uni, l’Espagne, le Brésil et le Mexique.

In the US, all clinical studies to support resubmission continue on track with re-filing expected by year end.
Aux Etats-Unis, toutes les études cliniques visant à soutenir le dépôt, prévu en fin d'année, d’une nouvelle demande sont en cours.

Other single-pill combinations in development are a combination of aliskiren and amlodipine, currently under regulatory review in the US and Europe, and a triple-combination therapy with aliskiren, amlodipine and a diuretic, expected to be submitted for US regulatory approval this year.
D’autres médicaments combinés en un comprimé unique sont en développement, tels que aliskirène et amlodipine, actuellement en cours d’examen aux Etats-Unis et en Europe, et une trithérapie avec aliskirène, amlodipine et un diurétique qu’il est prévu de soumettre cette année pour homologation aux Etats-Unis.

2010 outlook (Barring unforeseen events) At the half-year stage we raised our sales guidance to mid- to high-single-digit in constant currency, excluding Alcon. For the full year, Group sales will include four months of Alcon and this is expected to take constant currency sales growth into the low- to mid-teens.
Perspectives 2010 (sauf événements imprévus) En milieu d’année, nous avons relevé nos objectifs de chiffre d’affaires à un taux à un chiffre dans la partie moyenne à haute de la fourchette à taux de change constants, hors Alcon Pour l’exercice complet, le chiffre d’affaires du Groupe inclura quatre mois d’Alcon ce qui devrait hisser la croissance à taux de change constants à un taux à deux chiffres dans la partie basse à moyenne de la fourchette.

This expectation includes sales of A(H1N1) pandemic flu vaccines, which, year over year, is broadly neutral to overall sales growth.
Cette prévision comprend les ventes des vaccins A(H1N1) contre la pandémie de grippe comprises dans les deux années et ayant un impact neutre sur la hausse globale du chiffre d’affaires.

The formal EMA approval is expected by the end of this year.
L’autorisation formelle de l’EMEA est attendue pour la fin de cette année.

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.

As a rule, the psychological state of the 35-44 year-olds is found to be less favourable, especially as far as the more severe [4+] affections are concerned, which hit 16% of those belonging to this age group.
On remarque des dispositions psychologiques généralement moins favorables pour le groupe d’âge de 35-44 ans, surtout au regard des affections plus sévères [4+], qui atteignent 16 % des personnes de cet âge.

- At the end of the follow-up and potential referral, the suicidal individuals are contacted again by telephone (provided they have agreed to this) after a period of one month / three months / six months / a year, in order to maintain contact and assess their general evolution.
- au terme du suivi et de l’orientation éventuelle, un contact téléphonique est repris avec le suicidant (pour autant qu’il ait manifesté son accord) à l’échéance d’un mois / trois mois / six mois / un an afin de maintenir le lien et jauger l’évolution générale de la personne.